United Kingdom Menopause Treatment Market Insight
United Kingdom Menopause Treatment Market is growing at an 5.09% CAGR, by rising diabetes prevalence, increasing demand for cost-effective insulin therapies, NHS cost-containment initiatives, and expanding biosimilar adoption
United Kingdom Menopause Treatment Market Insights Forecasts to 2035
- The United Kingdom Menopause Treatment Market Size Was Estimated at USD 514.8 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.09% from 2025 to 2035
- The United Kingdom Menopause Treatment Market Size is Expected to Reach USD 845.5 Million by 2035
Notable Insights for United Kingdom Menopause Treatment Market
- By treatment type, hormone replacement therapy dominated, accounting for approximately 65% share in 2024, driven by effectiveness in managing vasomotor and hormonal symptoms.
- By therapy type, estrogen and combined hormone therapies dominated, holding approximately 72% share, due to increasing clinical adoption and NHS-supported menopause care.
- Approximately 15 million women in the UK are estimated to be peri-menopausal or menopausal, supporting strong demand for menopause treatment solutions nationwide.
Download the eBook (ToC)
- Around 60% of women seeking menopause treatment utilize hormone replacement therapies, while others prefer non-hormonal or lifestyle-based management approaches.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Menopause Treatment Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Menopause Treatment Market
- Pfizer
- Novo Nordisk
- Bayer
- Theramex
- Besins Healthcare
- Abbott Laboratories
- Viatris
- Gedeon Richter
- Astellas Pharma
- Others
Recent Developments:
- In March 2026: NICE recommended Fezolinetant (Veoza) for NHS use in treating moderate-to-severe menopausal hot flushes and night sweats when HRT is unsuitable, expanding non-hormonal treatment options in the United Kingdom menopause treatment market.
- In August 2025: Gedeon Richter launched Nalvee (10mg dydrogesterone) in the UK, reintroducing a dydrogesterone-only HRT option after 17 years, supporting personalised menopause treatment and expanding progestogen therapy choices.
Market Segmentation:
United Kingdom Menopause Treatment Market, By Treatment Type
- Hormone Replacement Therapy
- Non-Hormonal Therapy
- Complementary & Lifestyle Therapies
- Others
United Kingdom Menopause Treatment Market, By Route of Administration
- Oral
- Transdermal
- Injectable
- Vaginal
United Kingdom Menopause Treatment Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Women’s Health Centers
United Kingdom Menopause Treatment Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The market for UK Menopause Treatments is projected to grow strongly, driven by increased awareness about menopausal health, acceptance of hormone replacement therapy, and the growing support of the government/NHS towards women’s healthcare programs. According to experts, hormone replacement therapies will remain a dominant factor within the market due to the ability to manage symptoms and improve the quality of life. The development of advanced personalized hormone treatment, body-identical hormone therapy, and menopause care digital platforms will be instrumental in ensuring market growth until 2035.